NanoHeal: Bridging Bench to Bedside for Advanced Nanomaterials in Wound Care and Infection Prevention
( NanoHeal )
Interventions
Therapeutics
- Aaron Elbourne, RMIT University, Melbourne, Australia (Royal Melbourne Institute of Technology), Australia (Coordinator)
- Zlatko Kopecki, The University of South Australia, Australia (Partner)
- Claudia Contini, Imperial College London, United Kingdom (Partner)
- Andris Šutka, Riga Technical University, Institute of Materials and Surface Engineering – Chemical Engineering, Latvia (Partner)
- Anna Croft, Loughborough University, United Kingdom (Partner)
- Ulrich Schwaneberg, RWTH Aachen University, German, Germany (Partner)
- Patricia Hunt, Victoria University of Wellington, New Zealand (Observer)
Fungal infections are increasingly prevalent, posing a serious challenge for patients with wounds such as surgical incisions, diabetic ulcers, burn injuries, and more, where traditional treatments have failed. This is because fungal species are developing resistance to conventional treatments and are extremely underestimated in clinical management of chronic wounds. Despite advancements in antimicrobial treatments, fungal infections continue to impede healing and elevate risks of complications such as fungemia, invasive fungal disease, sepsis, and organ failure, underscoring the urgent need for innovative solutions. This is also true for bacterial infections, where AMR is causing current treatments to fail. To address this pressing issue, our multidisciplinary team of experts spanning chemists, physicists, biologists, material/protein engineers, and medical researchers has united. Leveraging nanotechnology, we are pioneering advanced antimicrobial therapies tailored to combat fungal infections in wounds. From rigorous laboratory testing to ensuring the safety and efficacy of these treatments, we aim to revolutionize wound care via providing treatments which prevent infection, decrease antimicrobial resistance, and heal wounds. We will develop and validate safe, effective, and targeted antimicrobial nanomaterials, which can be delivered to the site of wounds, promote healing, and have the ability to provide ‘on-demand’ treatment. Collaborating with a commercial partner, we will make our therapies widely accessible, transform patient outcomes, and save lives.